GoKawiilEli Lilly, Kariya and Baseline advance GLP-1 drugs for brain disorders
Eli Lilly presented early clinical data last month on brenipatide, a tirzepatide-related compound, for alcohol use disorder. Kariya Pharmaceuticals separately reported early results for KP405, a similar GLP-1 compound, in Parkinson's disease, while Baseline Therapeutics said it plans to begin a clinical trial of a GLP-1 compound for alcohol use disorder in early 2027.
GoKawiil's interpretation of the reporting above, not reported fact.
Academic researchers have studied GLP-1 pathways for brain conditions for years, but scientist Lorenzo Leggio notes the pharmaceutical industry only recently embraced this direction. Addiction researcher Christian Hendershot suggests that industry-backed trials could speed up development and potentially lead to FDA approvals for GLP-1-based addiction treatments within the next few years.
- Eli Lilly's brenipatide has shown first clinical results for alcohol use disorder.
- Kariya Pharmaceuticals is testing KP405, a related compound, for Parkinson's disease.
- Baseline Therapeutics plans a 2027 trial of a GLP-1 drug for alcohol use disorder.
Source: nature.com — Lenharo, 2026-10-13
Published there as: “Can GLP-1s heal the brain? Obesity drugs get a makeover for addiction and depression”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.